Smruthi Organics Limited is an India-based active pharmaceutical ingredients (API) manufacturer serving pharmaceutical companies. The Company’s segments include Bulk Drugs and Drugs Intermediates and Formulation. It manufactures API products in the anti-diabetic, anti-hypertension and anti-infectives therapeutic categories. Its products include Amlodipine Besilate, Losartan Potassium, Telmisartan, Metformin HCL, S-Amlodipine Besilate, S-Amlodipine Malelate, Valsartan, Vildagliptin, Teneligliptin, Ciprofloxacin HCL, Diloxanide Furoate, Norfloxacin, Pefloxacin Mesylate, Ticagrelor, and others. It caters to both the Indian domestic as well as the rest of the world (ROW) markets, with clients spanning Asia, the Americas, and Africa. The Company has two manufacturing facilities in Solapur, India. The API facility is spread across 22-acre land.
Smruthi Organics Limited Financial Highlights
- Revenue: Smruthi Organics Limited reported revenue of ₹102.09 crore in FY26 vs ₹126.10 crore in FY25. It showed a decrease of 19.04% on a yearly basis.
- Operating Profit: Smruthi Organics Limited reported an operating profit of ₹4.66 crore in FY26 vs ₹4.90 crore in FY25. It showed a decrease of 4.90% on a year-on-year basis.
- Net Profit: Smruthi Organics Limited reported a net profit of ₹3.43 crore in FY26 vs ₹3.56 crore in FY25. It showed a decrease of 3.65% on a yearly basis.
Smruthi Organics Limited Quarterly Result Highlights
- Smruthi Organics Limited reported revenue of ₹29.11 crore in Mar 2026, compared with ₹22.30 crore in Dec 2025, representing an increase of 30.54% on a quarter-on-quarter (QoQ) basis.
- Smruthi Organics Limited reported an operating profit of ₹1.74 crore in Mar 2026, compared with ₹1.63 crore in Dec 2025, representing an increase of 6.75% on a quarter-on-quarter (QoQ) basis.
- Smruthi Organics Limited reported a profit of ₹1.07 crore in Mar 2026, compared with ₹1.40 crore in Dec 2025, reflecting a decrease of 23.57% on a QoQ basis.
- The earnings per share (EPS) of Smruthi Organics Limited stood at ₹2.99 during Mar 2026.